Analysis Shionogi & Co., Ltd. (4507)
6/1/2024
Analysis of Shionogi & Co., Ltd. (4507)
Shionogi & Co., Ltd. is a pharmaceutical company based in Japan. Looking at the recent data, we can see that the stock price has been fluctuating around the 7000-7200 range. The Relative Strength Index (RSI) values indicate that the stock is not currently overbought or oversold, hovering around 40-45, suggesting a neutral position.The Moving Average Convergence Divergence (MACD) indicator shows negative values, indicating a bearish trend. The MACD line is below the signal line, and the MACD histogram is also negative, suggesting a potential downward movement in the stock price.
In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all above the current stock price, indicating a bearish sentiment.
Overall, based on the technical indicators, it seems that Shionogi & Co., Ltd. may be facing some downward pressure in the near term. Investors should closely monitor the stock price movement and any developments in the pharmaceutical industry that could impact the company's performance.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive trend of increasing earnings per share for both the upcoming quarters and the next fiscal years.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and healthy return on assets and equity. The balance sheet shows a current ratio slightly above 1, indicating good liquidity, but a high total debt to equity ratio. The income statement reveals significant revenue and EBITDA, with a positive diluted EPS and net income to common shareholders. Quarterly revenue and earnings growth have seen slight declines.
Moving on to stock statistics, the company has a low short ratio and short percent of shares outstanding, with a significant percentage held by institutions. The stock price summary shows a beta above 1, with the stock trading within a range of fifty-two-week low and high prices.
Valuation metrics indicate a high PEG ratio and price to book ratio, with the stock trading at a relatively high forward and trailing PE. The enterprise value is substantial compared to revenue and EBITDA, with a market capitalization reflecting this.
Lastly, dividends and splits information show a moderate payout ratio, with details on dividend dates, split history, and dividend yields provided.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. The operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. The net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. The company has been able to maintain a healthy EBITDA margin, which reached $129.2 billion in 2023.
7. The company's tax expenses have also increased over the years, in line with the growth in revenue and income.
8. The basic and diluted earnings per share (EPS) have shown an upward trend, indicating growth in profitability per share.
9. Overall, the financial performance of the company in terms of revenue and income has been positive and shows a healthy growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with cash and cash equivalents showing fluctuations.
3. Non-current assets consist mainly of investments and advances, with a significant portion in machinery, furniture, and equipment.
4. Total liabilities have also been increasing, with the highest value of $302,083,000,000 in 2022.
5. Current liabilities include short-term debt, accounts payable, and other current liabilities.
6. Non-current liabilities comprise long-term debt and other non-current liabilities.
7. Shareholders' equity has shown variations, with the highest value of $90,488,000,000 in 2019.
8. Common stock and retained earnings are the major components of shareholders' equity.
9. The company seems to be investing heavily in non-current assets, which might be driving the increase in total assets and liabilities.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
5. Investing activities include the sale and purchase of investments, capital expenditures, and acquisitions.
6. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still expected to be positive.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of 4507
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
